Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Off-the-Shelf CAR Therapy Shows Early Promise in Multiple Myeloma

December 5th 2020

ALLO-715, an off-the-shelf chimeric antigen receptor T-cell therapy that targets B-cell maturation antigen, elicited responses in heavily pretreated patients with relapsed/refractory multiple myeloma in early findings from a first-in-human study presented at the 2020 ASH Meeting.

bb21217 Continues to Showcase Durable Responses in Multiple Myeloma

December 5th 2020

December 5, 2020 - The enriched chimeric antigen receptor T-cell therapy bb21217 improved responses and also prolonged duration of response compared with non-enriched CAR T cells in patients with relapsed/refractory multiple myeloma.

Highly Refractory Myeloma Has Deep and Durable Responses With Ide-cel

December 5th 2020

December 5, 2020 - Patients with heavily pretreated multiple myeloma maintained durable responses with the chimeric antigen receptor T-cell therapy idecabtagene vicleucel in updated findings presented from the phase 1 CRB-401 trial.

Weekly Selinexor Regimen Shows Significant Benefit in Pretreated Multiple Myeloma

December 5th 2020

December 5, 2020 - A subgroup analysis from the phase 3 BOSTON study demonstrated that once weekly selinexor, bortezomib, and dexamethasone was superior to bortezomib and dexamethasone alone in patients with relapsed/refractory multiple myeloma who had received 1 to 3 prior therapies.

Dr. Mikhael on the Advances Made in Multiple Myeloma Treatment

December 2nd 2020

Joseph Mikhael, MD, discusses novel agents used to treat patients with multiple myeloma.

Dr. Costello on Considerations for Induction Therapy Selection in Multiple Myeloma

December 2nd 2020

Caitlin Costello, MD, discusses considerations for induction therapy selection in multiple myeloma.

Dr. Anwer on the Efficacy of CAR T-Cell Therapy in Multiple Myeloma

November 30th 2020

Faiz Anwer, MD, discusses the efficacy of CAR T-cell therapy in multiple myeloma.

Dr. Nagle on Investigational Cellular Therapies in Multiple Myeloma

November 30th 2020

Sarah Nagle, MD, assistant professor of medicine, School of Medicine, Oregon Health & Science University, discusses investigational cellular therapies in multiple myeloma.

Dr. Mikhael on Remaining Challenges in High-Risk Multiple Myeloma

November 24th 2020

Joseph Mikhael, MD, discusses remaining challenges in high-risk multiple myeloma.

Dr. Dorritie on Determining Transplant Eligibility in Multiple Myeloma

November 24th 2020

Kathleen A. Dorritie, MD, discusses transplant eligibility in multiple myeloma.

Dr. Lonial on Unanswered Questions With T-Cell Engagers in Myeloma

November 23rd 2020

Sagar Lonial MD, FACP, discusses unanswered questions with T-cell engagers in myeloma.

Denosumab Approved in China for Prevention of Skeletal-Related Events in Bone Metastases From Solid Tumors, Myeloma

November 23rd 2020

November 23, 2020 - The China National Medical Products Administration has approved denosumab for the prevention of skeletal-related events in patients with bone metastases from solid tumors and in those with multiple myeloma.

Dr. Mikhael on Unmet Needs in Triple-Class Refractory Multiple Myeloma

November 19th 2020

Joseph Mikhael, MD, discusses unmet needs in triple-class refractory multiple myeloma.

Usmani Highlights Impact of Latest Daratumumab Triplet Approval in Lenalidomide-Refractory Myeloma

November 19th 2020

Saad Z. Usmani, MD, FACP, discusses the significance of the FDA approval of daratumumab, carfilzomib, and dexamethasone in patients with relapsed/refractory multiple myeloma who have received at least 1 previous line of therapy.

FDA Lifts Clinical Hold on MELANI-01 Trial With CAR T Product UCARTCS1 in Myeloma

November 18th 2020

November 18, 2020 - The FDA has decided to lift the clinical hold placed on the phase 1 MELANI-01 trial, which is examining the CAR T-cell therapy UCARTCS1 as a treatment for patients with relapsed/refractory multiple myeloma.

Should All Elderly Patients With Newly Diagnosed Multiple Myeloma Receive Monoclonal Antibodies?

November 17th 2020

In light of the recent approvals of combination anti-myeloma regimens containing monoclonal antibodies, as well as the robust pipeline of novel targeted agents likely to be approved in the next year, there is much optimism in the field of multiple myeloma.

Dr. Costello on Tailoring Induction Therapy for Standard- and High-Risk Multiple Myeloma

November 16th 2020

Caitlin Costello, MD, discusses tailoring induction therapy for patients with standard-risk and high-risk multiple myeloma.

FDA, EMA Approval Sought for Subcutaneous Daratumumab Plus Pomalidomide/Dexamethasone in Relapsed/Refractory Myeloma

November 12th 2020

Regulatory applications have been submitted to the FDA and the European Medicines Agency for subcutaneous daratumumab for use in combination with pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma who have received at least 1 previous therapy.

Dr. Vesole on the Mechanism of Action of Belantamab Mafodotin in Multiple Myeloma

November 12th 2020

David H. Vesole, MD, PhD, discusses the mechanism of action of belantamab mafodotin-blmf in multiple myeloma.

Dr. Costello on Treatment Selection Considerations in Multiple Myeloma

November 10th 2020

Caitlin Costello, MD, discusses treatment selection considerations in multiple myeloma.